11 completed, 2 active not recruiting, 2 terminated, 2 unknown. 11 Phase 3, 4 Not applicable, 2 Phase 2, 1 Early Phase 1, 1 Phase 4.
Follow Double-Blind Method: new trials by email Literature Review of Double-Blind Method trials Research Report on Double-Blind Method
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DBPCT Effects of Omega-3 FA on Memory and Cognition in Peri- and Menopausal Women A Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Effects of Algae Omega-3 Fatty Acids on Memory and Cognition in Perimenopausal and Menopausal Women - Menopause | Not applicable | Active not recruiting | St. Mary's University, Twickenham | 42 | 2026-03-25 | 2026-09-10 |
| A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label) - Phosphomannomutase 2 Deficiency, PMM2-CDG | Phase 2 / Phase 3 | Active not recruiting | Glycomine, Inc. | 50 | 2025-07-09 | 2026-08-14 |
| Reducing the Negative Effects of Surgical Conditions Use of Double Layer Mask Against Electrocautery With Smoke Filter smoke filtering electrocautery device, double mask - Surgical Procedure, Unspecified | Not applicable | Completed | Ataturk University | 108 | 2023-11-01 | 2024-08-13 |
| Effect of IV Nalbuphine on Nausea and Vomiting Following Intrathecal Morphine nalbuphine on N and V and pain with intrathecal morphine onInguinal hernia repair surgery. randomized, prospective, double blinded and placebo-controlled trial study. - Inguinal Hernia | Not applicable | Unknown | Assiut University | 80 | 2023-06-01 | 2023-05-08 |
| Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301. CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg - ADHD, ADHD - Combined Type | Phase 3 | Completed | Cingulate Therapeutics | 26 | 2022-12-29 | 2026-07-02 |
| An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older randomized, double-blinded, placebo-controlled - Prevention of COVID-19 Caused by SARS-CoV-2 | Early Phase 1 | Unknown | Yu Qin | 3300 | 2022-12-27 | 2023-01-11 |
| Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP Double-blind 200 mg imsidolimab, Placebo, Open-label 200 mg imsidolimab - Generalized Pustular Psoriasis | Phase 3 | Terminated | Vanda Pharmaceuticals | 42 | 2022-04-21 | 2026-03-27 |
| Glutenfree, Gut Microbiota and Metabolic Regulation Randomized, controlled trial (RCT) with parallel arms and double blinded - Celiac Disease | Not applicable | Completed | Oslo Metropolitan University | 30 | 2021-09-01 | 2024-08-12 |
| A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC) Double-Blind 0.2mg CBP-307, Double-Blind Placebo, Open-label CBP-307 - Moderate to Severe Ulcerative Colitis | Phase 2 | Completed | Connect Biopharm LLC | 145 | 2019-02-27 | 2024-05-06 |
| Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label) - Dyspnea, Hypertension | Phase 3 | Withdrawn | The Medicines Company | 2014-08-01 | 2020-10-19 | |
| A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211) Sitagliptin, Atorvastatin, Placebo to sitagliptin - Type 2 Diabetes Mellitus | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 166 | 2011-10-24 | 2018-07-26 |
| Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors CP-690,550, Placebo - Arthritis, Rheumatoid | Phase 3 | Completed | Pfizer | 399 | 2009-10-01 | 2018-12-19 |
| A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate CP-690,550, Placebo - Arthritis, Rheumatoid | Phase 3 | Completed | Pfizer | 800 | 2009-03-01 | 2024-05-16 |
| An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain Tramadol Hydrochloride Plus Acetaminophen (Open-Label), Tramadol Hydrochloride Plus Acetaminophen (Double-Blind), Placebo (Double-Blind) - Pain | Phase 3 | Completed | Janssen Pharmaceutical K.K. | 321 | 2008-06-01 | 2013-09-26 |
| Hyper- and Hypokalemic Periodic Paralysis Study Dichlorphenamide (double-blind), Placebo (double-blind), Dichlorphenamide (open-label) - Hyperkalemic Periodic Paralysis, Hypokalemic Periodic Paralysis | Phase 3 | Completed | University of Rochester | 71 | 2007-06-01 | 2017-06-14 |
| Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB - Rheumatoid Arthritis | Phase 3 | Completed | Bristol-Myers Squibb | 431 | 2005-02-01 | 2015-03-24 |
| A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy RASi plus carvedilol - Chagas Cardiomyopathy, Heart Failure | Phase 4 | Completed | Federal University of Minas Gerais | 42 | 2003-05-01 | 2015-08-13 |
| Remission in Subjects With Crohn's Disease, 1 Year Phase Double-blind (DB) adalimumab placebo, DB adalimumab 40 mg eow, DB adalimumab 40 mg ew - Crohn's Disease | Phase 3 | Completed | Abbott | 276 | 2002-08-01 | 2011-04-11 |
Arthritis, Rheumatoid (3) · Ataxia (1) · Attention Deficit Disorder with Hyperactivity (1) · Cardiomyopathy, Dilated (1) · Celiac Disease (1) · Chagas Cardiomyopathy (1) · Chronic Pain (1) · Congenital disorder of glycosylation type 1A (1) · Crohn Disease (1) · Diabetes Mellitus, Type 2 (1) · Dyspnea (1) · Heart Failure (1) · Hernia, Inguinal (1) · Hypertension (1) · Hypokalemic Periodic Paralysis (1)
Pfizer (2) · Abbott (1) · Assiut University (1) · Ataturk University (1) · Bristol-Myers Squibb (1) · Cingulate Therapeutics (1) · Connect Biopharm LLC (1) · Federal University of Minas Gerais (1) · Glycomine, Inc. (1) · Janssen Pharmaceutical K.K. (1) · Merck Sharp & Dohme LLC (1) · Oslo Metropolitan University (1) · St. Mary's University, Twickenham (1) · The Medicines Company (1) · University of Rochester (1)
United States (10) · Australia (4) · Brazil (4) · Poland (4) · South Korea (4) · Spain (4) · Canada (3) · Czechia (3) · France (3) · Germany (3) · Italy (3) · Taiwan (3) · United Kingdom (3) · Belgium (2) · China (2)
Ann Childress, MD (1) · Anne Camez, MD (1) · Fernando A Botoni, MD, PhD (1) · Michael McDermott, Ph.D. (1) · Rabi Tawil, M.D. (1) · Robert C. Griggs, M.D. (1) · Suzhou Connect (1) · William F Peacock, MD, FACEP (1)
PMID 25047021, PMID 26275429, PMID 28143815, PMID 29949132, PMID 30177460, PMID 32816215, PMID 33059710, PMID 33127856, PMID 34870800, PMID 34921355, PMID 35577477, PMID 36526796, PMID 36600185, PMID 36601090, PMID 36814062, PMID 36931693, PMID 37453736, PMID 37925660, PMID 38958913, PMID 39192350, PMID 17383291, PMID 18055472, PMID 22344964, PMID 23294500, PMID 23348607, PMID 25186034, PMID 27889300, PMID 28941219, PMID 29380251, PMID 29761420, PMID 29856176, PMID 30666826, PMID 33057725, PMID 35382883, PMID 41448717, PMID 42047557